Medpace Holdings, Inc. $MEDP Shares Sold by Rhumbline Advisers

Rhumbline Advisers trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 63,582 shares of the company’s stock after selling 3,889 shares during the quarter. Rhumbline Advisers owned approximately 0.23% of Medpace worth $32,691,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. NewEdge Advisors LLC raised its stake in shares of Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after buying an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. raised its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Sivia Capital Partners LLC bought a new position in Medpace during the 2nd quarter worth approximately $296,000. Finally, IFP Advisors Inc grew its position in shares of Medpace by 223.3% in the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after acquiring an additional 134 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 270,533 shares of company stock worth $163,122,826. 20.30% of the stock is owned by corporate insiders.

Medpace Price Performance

Shares of Medpace stock opened at $428.03 on Friday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The business’s fifty day moving average price is $567.52 and its two-hundred day moving average price is $538.35. The company has a market capitalization of $12.15 billion, a P/E ratio of 27.98, a PEG ratio of 2.05 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period last year, the company earned $3.67 earnings per share. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of several research analyst reports. Truist Financial reduced their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday. BMO Capital Markets restated a “market perform” rating on shares of Medpace in a research report on Wednesday. TD Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. Barclays dropped their price objective on shares of Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a research note on Wednesday. Finally, Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Four equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $487.36.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.